

# Marco Calabr

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8178166/marco-calabro-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

274

citations

11

h-index

15

g-index

29

ext. papers

334

ext. citations

4

avg, IF

2.73

L-index

#	Paper	IF	Citations
26	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 44, 271-8	5.5	35
25	Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. <i>Journal of Affective Disorders</i> , <b>2015</b> , 179, 88-94	6.6	29
24	Progress and prospects in pharmacogenetics of antidepressant drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 1157-68	5.5	22
23	CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 689-701	2.6	19
22	Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by Schizophrenia and Bipolar Disorder and controls. <i>Psychiatry Research</i> , <b>2015</b> , 228, 945-9	9.9	19
21	FMO3 allelic variants in Sicilian and Sardinian populations: trimethylaminuria and absence of fish-like body odor. <i>Gene</i> , <b>2013</b> , 515, 410-5	3.8	16
20	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2017</b> , 267, 723-735	5.1	14
19	A molecular pathway analysis informs the genetic background at risk for schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2015</b> , 59, 21-30	5.5	14
18	Biological substantiation of antipsychotic-associated pneumonia: Systematic literature review and computational analyses. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187034	3.7	14
17	Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. <i>Neuropsychobiology</i> , <b>2016</b> , 74, 159-168	4	14
16	Identification of a novel CCM2 gene mutation in an Italian family with multiple cerebral cavernous malformations and epilepsy: a causative mutation?. <i>Gene</i> , <b>2013</b> , 519, 202-7	3.8	12
15	The microtubule-associated molecular pathways may be genetically disrupted in patients with Bipolar Disorder. Insights from the molecular cascades. <i>Journal of Affective Disorders</i> , <b>2016</b> , 190, 429-438	6.6	10
14	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. <i>Advances in Therapy</i> , <b>2018</b> , 35, 1656-1670	4.1	9
13	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for and. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2019</b> , 17, 364-368	3.4	8
12	Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , <b>2016</b> , 370, 162-166	3.2	7
11	Alzheimer's Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters. <i>Neuropsychobiology</i> , <b>2019</b> , 78, 79-85	4	6
10	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. <i>Human Psychopharmacology</i> , <b>2018</b> , 33, e2682	2.3	6

9	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , <b>2020</b> , 720, 134754	3-3	4
8	Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2020</b> , 18, 231-240	3-4	4
7	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. <i>Advances in Therapy</i> , <b>2017</b> , 34, 1482-1497	4-1	3
6	Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer's disease. <i>Molecular Biology Reports</i> , <b>2020</b> , 47, 191-200	2-8	3
5	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. <i>Journal of Molecular Neuroscience</i> , <b>2018</b> , 64, 62-74	3-3	3
4	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2021</b> , 19, 46-52	3-4	2
3	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , <b>2021</b> , 28, 4296-4320	4-3	1
2	FKBP5 Gene Variants May Modulate Depressive Features in Bipolar Disorder. <i>Neuropsychobiology</i> , <b>2019</b> , 78, 104-112	4	0
1	Possible biomarkers modulating haloperidol efficacy and/or tolerability. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 507-29	2-6	